Scribe Therapeutics filed for an IPO aimed at funding its clinical push for lipid-lowering genetic medicines, targeting a potential $96 million raise. The filing outlines planned use of proceeds to advance its lead gene-silencing program, STX-1150, in an ongoing Phase 1 study and to move additional assets such as STX-1400 and STX-1200 toward clinical development. STX-1150 is designed to shut down PCSK9, with Scribe starting a first-in-human study in Australia that includes up to 64 adults with elevated LDL-C and increased ASCVD risk. The company expects topline LDL-C data in the first half of 2027. The IPO also highlights the founders’ strategy for next-generation RNA interference-style therapies, including potential long-dosing intervals intended to compete with established gene-targeted approaches.